-
Mashup Score: 3
“This was a very special moment, delivering the news to this patient that his cancer is now undetectable following the treatment with 2 doses of 8 GBq of 67Cu-SAR-bisPSMA,” says Luke Nordquist, MD, FACP.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Licensing agreement reached for contrast agent for use in patients with prostate cancer - 8 day(s) ago
A late phase 3 trial evaluating the agent is underway at several clinics in Europe.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 9
“I think that this field is going to continue to evolve, especially when we think about how to incorporate PSMA-PET findings into our clinical care,” says Todd M. Morgan, MD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Integration of family history, germline genetics is important in defining prognosis of prostate cancer - 19 day(s) ago
“I think the greatest implication the study has is that it tells us that family history and germline genetics independently provide complementary information that’s important for risk stratification of localized prostate cancer,” says Keyan Salari, MD, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 6Dr. Salari on family history, germline genetic risk in favorable-risk prostate cancer - 22 day(s) ago
“What we found is that over a third of patients, 36%, had positive family history of either prostate, breast, or pancreatic cancer. And if you had this type of a family history, there was nearly a two-fold risk of dying of prostate cancer in the long term,” says Keyan Salari, MD, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Urologist discusses collaborating with nuclear medicine when using PSMA-PET for prostate cancer - 29 day(s) ago
“At Northwestern Medicine, we have very extensive and very deep experience with PET-PSMA-based imaging,” says Edward M. Schaeffer, MD, PhD.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 0Evolving Treatment Landscape in Prostate Cancer - 1 month(s) ago
Experts on prostate cancer discuss how treatment has evolved over the years, focusing on doublet and triplet therapy and their utility.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1Annual prostate cancer cases are projected to rise, new data show - 1 month(s) ago
The authors also project an 85% increase in the number of deaths from prostate cancer per year, which would bring the total number from 375,000 in 2020 to nearly 700,000 by 2040.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1
“I predict the future treatment for men with truly high-risk prostate cancer will see a fusion of what was thought to be standard local treatments combined with multimodality therapies that were initially impactful only in the more advanced disease state,” writes Michael S. Cookson, MD, MMHC, FACS.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 1FDA clears IND for 225Ac-J591 in advanced prostate cancer - 1 month(s) ago
Convergent plans to conduct phase 2 clinical trials of 225Ac J591 in prostate cancer in 2024, with a registrational program set to begin in 2025.
Source: www.urologytimes.comCategories: General Medicine News, UrologyTweet
The first patient to be dosed with 2 cycles of 67Cu-SAR-bisPSMA at 8 GBq has achieved a complete response per RECIST v1.1 criteria. #pcsm #urology #urologist Read more: https://t.co/7rX9Ut9H6g